Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of Vonafexor in Healthy Men
NCT04037618Phase 1Completed
- Sponsor
- ENYO Pharma
- Start
- Jul 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vonafexor in hepatitis B (HBV) and Nonalcoholic steatohepatitis (NASH), sponsored by ENYO Pharma. Primary endpoints: Radioactivity-time profiles in whole blood and plasma, Maximum observed concentration and 5 more. Started Jul 2019; status: completed.
02
Drugs
vonafexor
03
Conditions
hepatitis B (HBV)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04037618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04037618.